Scrip 100: Novo Nordisk's US sales growth comes at a price
This article was originally published in Scrip
Executive Summary
A look at data generated through Scrip's annual number crunch of the pharmaceutical industry, the Scrip 100, suggests Novo Nordisk's impressive sales successes in recent years are coming at a cost.